Next Article in Journal
The Real-World Burden of Moderate-to-Severe Psoriasis in Patients Under Systemic Treatment from Baltic Countries: Data from the CRYSTAL Observational Study
Previous Article in Journal
First Clinical Results of Hyperopic Eyes Treated with a New Ablative Solid-State Laser
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 61
Issue 3
10.3390/medicina61030396
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association of Voltage-Gated Potassium Channel Polymorphisms with the Risk and Prognosis of Epilepsy in the Saudi Population: A Case–Control Study

by
Mansour A. Alghamdi
1,2,*,
Laith N. AL-Eitan
3,*,
Mansour Y. Otaif
4,
Doaa M. Rababa’h
3,
Maryam K. Alasmar
3,
Abdulaziz M. Al-Garni
5,
Rayyh A. M. Saleh
6,7 and
Nawal F. Abdel Ghaffar
8,9
1
Department of Anatomy, College of Medicine, King Khalid University, Abha 62529, Saudi Arabia
2
Genomics and Personalized Medicine Unit, The Center for Medical and Health Research, King Khalid University, Abha 62529, Saudi Arabia
3
Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan
4
Department of Pediatric, Neurology Section, Abha Maternity and Children Hospital, Abha 62562, Saudi Arabia
5
Department of Medicine, College of Medicine, King Khalid University, Abha 62529, Saudi Arabia
6
Clinical Pathology, Faculty of Medicine (for Girls), Al-Azhar University, Cairo 11884, Egypt
7
Laboratory and Blood Bank Department, Aseer Central Hospital, Abha 62523, Saudi Arabia
8
Neurology Department, Kasr Al Ainy Hospital, Faculty of Medicine, Cairo University, Giza 12613, Egypt
9
Neurology Department, Aseer Central Hospital, Abha 62523, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Medicina 2025, 61(3), 396; https://doi.org/10.3390/medicina61030396
Submission received: 1 February 2025 / Revised: 21 February 2025 / Accepted: 22 February 2025 / Published: 25 February 2025
(This article belongs to the Section Neurology)
Versions Notes

Abstract

Background and Objectives: Epilepsy, known as an unprovoked seizure, arises from the human brain. Genetics plays a fundamental role in the development and progression of the disorder. This study aimed to investigate the influence of voltage-gated K+ channels on the risk of epilepsy. Materials and Methods: Several genetic variants were examined using PCR sequencing. This case–control study was conducted on 296 individuals who were diagnosed with epilepsy, in addition to 293 healthy participants. Results: This study revealed that within KCNAB1, both rs3755631 and rs4679773 are correlated with epilepsy, and the p-values = 0.04 for both allelic associations. In addition, regarding the KCNJ10 gene, we found that rs2820585, rs946420, rs1186679, rs61822012, and rs1186685 were significantly correlated with epilepsy risk (p-values = 0.034, 0.045, 0.021, 0.048, and 0.018), respectively. Conclusions: From the current study, we conclude that voltage-gated potassium channels can impact epilepsy risk and can also interfere with the prognosis of epilepsy.

1. Introduction

Epilepsy is a common neurological disorder that is characterized by unprovoked seizures generated by an abnormal electrical flow from a specific part of the human brain [1,2]. Approximately 50 million people worldwide are affected by epilepsy, making it one of the most common neurological disorders. Epilepsy can affect both genders of all races and affect people of all ages. However, the prevalence of epilepsy among men is slightly higher than among women [3].
The last documented prevalence study on active epilepsy cases in the Kingdom of Saudi Arabia (KSA) was conducted in 2001, estimating a prevalence of 6.5 per 1000 individuals [4]. Cultural understanding and acceptance of epileptic patients have increased over the years in the Saudi population as more people have become aware of the disease, and general knowledge has increased [5,6]. This led to more acceptance for epileptic patients in different parts of the community and community-based activities [5,6].
The etiology of epilepsy is a significant determinant of the clinical manifestation and prognosis of the disease [7]. Several prominent factors have been identified as part of the etiology of epilepsy. Epilepsy disorder is a complex condition in which both environmental and genetic factors can interfere with the progression and development of the disease [8]. Brain injuries during the early stages of development of people; brain infections; brain trauma; and brain conditions such as stroke, tumor, and blood vessel problems are the commonly recognized causes of epilepsy [9]. Genetic defects can result in an epileptic seizure known as genetic (non-inherited) epilepsy [10]. Furthermore, environmental factors can trigger genetic variation within a person’s genome throughout their life [11]. However, the family history of an individual with epilepsy is a significant risk factor for the development of the disease and can be determined as inherited epilepsy [12].
Potassium (K) channels are crucial in the demonstration of genetic epilepsy. The K channel family is the largest among ion-gated channels and comprises more than 70 human genes that encode different α subunits [13]. These channels are essential for neuronal excitability, and several epileptic phenotypes have been attributed to functional impairment in potassium channels (K+) [14]. Voltage-gated K+ channels (Kv) regulate action potentials, modulate neurotransmitters, and control electrical properties [15]. They also regulate various pathways of neuronal life and death, such as apoptosis, channel phosphorylation, or cell proliferation [16].
The KCNA1 gene is located on chromosome 12 and encodes the voltage-gated K+ channel subunit Kv1.1 [17]. Several heterozygous point mutations have been identified within this gene that cause loss of function and subsequently alter the properties of the channel and are associated with reduced currents [18]. This alteration results in epileptic phenotypes such as generalized or partial seizures associated with episodic ataxia (EA) [19,20]. On the other hand, a complete loss of KCNA1 function has been implicated in neonatal epileptic encephalopathy (NEE) [21].
The KCNA2 gene is located in chromosome 1 and encodes an α subunit of the Kv1.2 channel. This gene has been involved in epileptic encephalopathy (EE) [22], ataxia, and myoclonic epilepsy [23]. Many genetic polymorphisms within KCNA2 have been extensively investigated, and several were correlated with epilepsy risk and have been reported in patients with BFNIS, GEFS+, and Dravet syndrome [24]. Variant effects on K channel activity fluctuate; some confer loss of function, such as p.Ile263Thr and p.Pro405Leu, while others manifest gain of function, such as p.Arg297Gln and p.Leu298Phe [25]. The voltage-gated potassium channel, Kv8.2, is encoded by KCNV2. Kv8.2 can interact functionally with Kv2 subunits, impacting membrane translocation and channel properties [26]. The p. Arg7Lys variant has been reported to influence K channel function by decreasing the delayed rectifier K+ current in neurons and is recognized among patients with febrile and febrile partial seizures. Furthermore, p.Met285Arg within KCNV2 is associated with epileptic encephalopathy and severe refractory epilepsy [20].
KCNAB2 is another gene encoded for the voltage-gated potassium channel Kvβ2 and has been involved with severe epilepsy. Hemizygous deletion of KCNAB2 results in loss of function of channel activity [27]. KCNJ10 and KCNJ9 have also been correlated with the risk of epilepsy. KCNJ10 encodes Kir4.1, and p.Arg271Cys within the gene is responsible for susceptibility to seizures, even though it does not confer changes in channel function and structure [28]. p. Arg65Cys is another recessive mutation of the KCNJ10 gene that causes channel loss of function and is related to epilepsy syndromes such as EAST or SeSAME [29,30]. A summary of the previous literature on potassium channels and epilepsy risk is presented in Table S1.
Voltage potassium channels are significant predictors of the clinical outcome of epilepsy. Different Kv channels may be implicated in specific epilepsy subtypes, influencing clinical outcomes such as seizure frequency and severity. In addition, understanding the phenotypic associations with Kv channel variants can guide personalized treatment strategies based on the specific channel involved [31].
Previously, we have studied the association of several sodium voltage-gated channel genes with epilepsy development and prognosis [32]. There is not enough information about the genetic contribution towards epilepsy in the Arab region. Genetic correlation with epilepsy prevalence has been tested in Arab Jordanian epilepsy patients. They were tested for polymorphisms in CYP3A5 [33], MTHFR [34], GRM4 [35], CHRM2 [33], SCN2A [35], ZNF498 [33], SCN3B [35], and ABCC2 [34].
This study is part of an ongoing project on epilepsy in Saudi Arabia, focusing on its clinical and genetic aspects [32]. It aims to identify genetic variants associated with genetic epilepsy, assess their correlation with clinical phenotypes, evaluate gene–environment interactions, and determine the prevalence of specific genetic risk factors. Additionally, it seeks to enhance understanding of epilepsy’s genetic basis, supporting future pharmacogenomic drug development and improved treatment strategies.

2. Materials and Methods

2.1. Study Subjects and Design

The present study is part of an ongoing larger project to study epilepsy in Saudi Arabia, including clinical and genetic aspects of the disease [32]. The same cohort of previously published work has been used in this study, which comprised 589 Saudis of Arab descent, 296 of whom were diagnosed with epilepsy, in addition to 293 blood samples from healthy participants [32]. Epileptic patients were recruited from various healing facilities in the kingdom between November 2019 and April 2021; clinical data were obtained from their medical records. Written informed consent was obtained from all study subjects and the legal guardians of minors before this study’s commencement after they were told about the objective and aim of this study. Ethical approval was obtained for the conduct of this study (the Research Ethics Committee of King Khalid University with the approval number ECM#2019-38).
Gender and the relatively small sample size could introduce selection bias. However, potential bias due to population stratification was minimized, as the Saudi Arabian population is relatively homogeneous. Furthermore, there were no significant differences between the case and control groups regarding basic demographic characteristics. This study included patients diagnosed with epileptic seizures, including those with generalized, focal, or combined epilepsy, all of whom underwent EEG. Both refractory and non-refractory epilepsy patients were included, while individuals with non-epileptic seizures were excluded. Additional exclusion criteria included pregnancy; a history of drug abuse; the use of medications that could interfere with study outcomes; the presence of comorbid conditions that may exacerbate epilepsy; and structural epilepsy, which was ruled out through neuroimaging.

2.2. Polymorphism Selection, DNA Extraction, and Genotyping

When analyzing specific polymorphisms KCNAB1 and KCNJ10, we followed a systematic approach that included a review of previous studies, functional relevance, gene function, and pathway involvement. On the other hand, variants have been excluded based on criteria such as lack of association with epilepsy, low minor allele frequency, and technical limitations.
After collecting blood samples, genomic DNA was extracted directly according to the Wizard Genomic DNA Purification Kit (Promega Corporation, Madison, WI, USA). The quality and quantity of the purified DNA were then achieved by employing agarose gel electrophoresis and the Nano-Drop ND-1000 UV-vis Spectrophotometer (BioDrop, Cambridge, UK), respectively. The DNA samples were diluted with nuclease-free water to achieve a final concentration of 20 ng/μL and a final volume between 50 and 500 μL. The samples were genotyped at Gehrmann Laboratories, the University of Queensland, QLD 4072, using the Sequenom MassARRAY® system (iPLEX GOLD) (Sequenom, San Diego, CA, USA) [36].

2.3. Statistical Analysis

All SNPs were detected to fulfill the Hardy–Weinberg equilibrium (p2 + 2pq + q2 = 1). The genotypic and allelic association was conducted using snpSTAT, 2006 Institut Català d’Oncologia software. Data description and phenotype–genotype analyses were conducted using JASP 0.16 software. For the present study, statistical significance was established at a p-value < 0.05. In this case–control study, both cases and controls were analyzed in the same batch.
For case–control studies, the sample size can be calculated using formulas incorporating the above factors. An example formula is as follows: n = (Zα/2 + Zβ)2 (p1(1 − p1) + p2(1 − p2))/(p1 − p2)2 [37], where n = required sample size.

3. Results

3.1. Patient Characteristics

The data collected on the participation of epilepsy patients in the current study revealed no variation in the gender distribution between cases. Furthermore, the ages of the patients ranged from infant to 35 years in the patients. The average body mass index (BMI) was (23.2 ± 7.789). Interestingly, most of the participants were diagnosed with generalized epilepsy, and 55% of the patients had relapsed, while 79% had periodic epilepsy. We also found that 33.9% of patients had a family history of epilepsy, while 11.9% had a history of febrile seizures. The predominant seizure type was motor seizure, according to the data of this study. The general and clinical characteristics of epilepsy patients are summarized in Table 1.

3.2. Genetic Variants of KCN Genes

Table 2 and Table S2 describe the investigated SNPs in the genes of voltage-gated potassium channels for both cases and controls. This study included 296 patients in addition to 293 controls. The table shows the minor alleles and their frequencies, the p-value of HWE, in addition to the chromosomal position of the SNPs. Non-polymorphic SNPs and those not fulfilling the HWE were excluded from this study. The results of the HWE analysis show that the alleles are typically distributed among the patients, except rs16826199 of KCNAB1 (p-value = 0.044) and rs7029012 of KCNV2 (p-value = 0.033). Cultural understanding of the Saudi population could explain this, as consanguineous marriage is highly found in the Arab Saudi population, thus making the population nearly genetically isolated. This might have led to the abnormal distribution of the G allele of rs16826199. This trend could be seen in the controls in the A allele of rs4295133; G allele of rs2720281, rs17352408, and rs2280561; and, finally, the C allele of rs1546750 of the KCNAB1 gene. It is also seen in the C allele of rs12402969 and the A allele of rs1186675 of the KCNJ10 gene.

3.3. Genetic Association Between Genetic Variants of Voltage-Gated Potassium Channels and Epilepsy

Table 3 and Table S3 illustrate the genotypic and allelic frequencies of healthy individuals and patients, in addition to showing the p-values that define the correlation between each variant and epilepsy. Within KCNAB1, our finding asserts that both rs3755631 and rs4679773 are correlated to epilepsy; the p-value = 0.04 for both allelic associations. To elucidate this in detail, according to Table 3, the variant allele (G) of rs3755631 was higher among cases when compared to within controls. However, the same scenario applies to the variant allele (G) of rs4679773; therefore, we contend that these variants can influence the risk of epilepsy.
However, the genotype (A/A) of rs2820585 in the KCNJ10 gene was slightly lower (2%) in the group of patients than among healthy individuals (2.8%). In this regard, a statistically significant association was detected for the genotypic association (p-value = 0.034), and therefore, we suggest that the variant A/A genotype may confer a reduced risk of epilepsy. The variant genotype A/A of rs946420 in the KCNJ10 gene can also be designated as a protective factor against epilepsy (p-value = 0.045) (Table 3). In the same gene, we also inspected a compelling association between rs1186679 and epilepsy (p-value = 0.021). We propose that variant T/T might be involved in the development and progression of epilepsy. According to our results, rs61822012 and rs1186685 KCNJ10 were associated with epilepsy (p-value = 0.048 and 0.04), respectively.

3.4. Association of Clinical Factors of Epilepsy with Voltage-Gated K Channel Genes’ Variation

In light of the results of this study, several clinical features of epilepsy were correlated with variants of the KCN genes (Table 4, Tables S4 and S5). Age at diagnosis was associated with KCNAB1/rs1546750 and KCNJ10/rs946420, rs61822012, and rs1186685 (p-values = 0.045, 0.01, 0.01, and 0.01, respectively). Additionally, the findings revealed that the duration of the first seizure was related to KCNV2/rs10967705 and KCNJ10/rs11265313 (p-values = 0.005 and 0.002). Vitamin D was also associated with KCNA2/rs3887820 (p-value = 0.022). Furthermore, Vitamin B12 and KCNAB1/rs728382 were significantly correlated (p-value = 0.031) (Table 4).
A significant association between gender and KCNJ10/rs1053074 was reported (p-value = 0.004). Relapse was associated with KCNAB1/rs992353 (p-value = 0.008), while the history of febrile seizure was found to be related to KCNA1/rs7974459 (p-value = 0.027) and KCNJ10/rs1186689 (p-value = 0.020). Furthermore, potential interactions between periodic seizures and KCNAB1/rs4679773, KCNJ10/rs2820585, rs1186679, rs4656873, and rs1890532 were investigated (p-values = 0.029, 0.039, 0.038, 0.010, 0.015). The time to remission was correlated with KCNJ10/rs4656873 and rs17375748 (p-values = 0.049, 0.001). Furthermore, drug response was associated with KCNAB1/rs2280031, KCNJ10/rs2820585, rs946420, rs1186679, rs61822012, and rs1186685 (p-values = 0.042, 0.008, 0.006, 0.008, 0.004, 0.006). It was found that a family history of epilepsy was influenced by KCNA1/rs2227910, KCNAB1/rs4679773, and KCNJ10/rs12122979 (p-values = 0.039, 0.011, 0.047). Finally, epilepsy classification was correlated with KCNV2/rs10967728 and KCNAB1/rs1551066, KCNJ9/rs2753268 (p-values = 0.033, 0.020, 0.024) (Table 5).

4. Discussion

Epilepsy is a neurological disorder that occurs due to excessive electrical discharges in the brain that are known as seizure episodes [1]. Several essential factors affect the development and progression of the disorder; however, it is plausible that both the environment and genetics are fundamental when exploring the etiology of epilepsy [32]. The previous literature has focused on specific genes depending on their involvement in neurological pathways [38]. Voltage-gated potassium channels were comprehensively studied in relation to the risk of epilepsy, and many polymorphisms have been identified as biomarkers involved in epilepsy [39].
Voltage-gated potassium channels are critical in epilepsy genetics by influencing neuronal excitability, seizure susceptibility, and treatment responses. Their genetic mutations can lead to significant alterations in neuronal function, contributing to the development and progression of epilepsy. Key points highlight their specific role, including the Regulation of Neuronal Membrane Potential by Repolarization, where Kv channels facilitate the repolarization phase of action potentials. In addition, an Impact on Excitability occurs when a dysfunction in Kv channels can lead to prolonged depolarization and increased neuronal excitability, leading to the hyperexcitability characteristic of epilepsy [40].
In this study, we revealed the association between different genetic variants of voltage-gated potassium channels and epilepsy risk, and, accordingly, we suggest that both rs3755631 and rs4679773 of KCNAB1 are correlated with epilepsy. We also contend that the variant alleles (G) of both polymorphisms can influence the risk of epilepsy. Other studies support the fact that KCNAB1 is a vulnerable gene for lateral temporal epilepsy, causing it to alter susceptibility to focal epilepsy [41,42]. We also that the A/A variant genotype of rs2820585 in KCNJ10 may confer a reduced risk of epilepsy, as well as the A/A genotype of rs946420 in KCNJ10. Furthermore, a compelling association between rs1186679 and epilepsy was detected, and we propose that the variant T/T could be involved in the development and progression of epilepsy. Based on our results, we infer that both rs61822012 and rs1186685 KCNJ10 are involved in the risk of epilepsy. However, in contrast to our findings, rs1186685 and rs12122979 were not associated with the focal epilepsy susceptibility in the Chinese Han population [43]. In a study made in Jordan, it was shown that genes related to the potassium ion channel protein are genetically associated with the diagnosis of epileptic seizures in patients [44].
Furthermore, in the current study, we investigated the association of the clinical factors of epilepsy with the voltage-gated potassium channel gene variant. It is intelligible that definite genotypes can contribute to variations in epilepsy phenotypes. Age at diagnosis was correlated with KCNAB and KCNJ10. We also found that KCNV2 and KCNJ10 can interfere with the duration of the first seizure. The levels of Vitamin D and Vitamin B12 levels among epilepsy patients were influenced by KCNA2 and KCNAB1, respectively. Vitamin D is significant as a prospective intervention for epilepsy, and it has been declared that among epilepsy patients, the level of vitamin D is low [45,46]. In this regard, detecting the genetic variant of voltage-gated potassium channel genes is fundamental as it may manipulate the level of such essential vitamins.
The incidence of epilepsy is slightly higher in men than in women [47], and according to our results, gender and the KCNJ10 variant were correlated. We assert that genetic variants of KCN genes may impact the prevalence of epilepsy among men and women. Genetic variants can be used as predictive factors for the recurrence of epilepsy, and in light of our findings, KCNAB1 was found to impact relapse in epilepsy. KCNA1 influenced the history of febrile seizures and the history of epilepsy. Our findings also infer that KCNAB1 and KCNJ10 may enhance periodic spasms. Genetic variation can modulate the response to medications. In this study, we implied that KCNJ10 and KCNAB1 may mediate drug responsiveness in epilepsy patients. Furthermore, the time to remission was correlated with KCNJ10, and KCNV2 and KCNJ9 influenced the classification of epilepsy. However, we cannot generalize the findings of this study simply due to the population’s ethnicity divergence.
Over the last few years, knowledge awareness and cultural understanding about epilepsy diagnosis have increased [48]. This has been reflected through more cultural acceptance of epilepsy patients in different aspects of life [49]. However, there remains a significant gap in knowledge regarding the genetic associations of epilepsy in the Arab region. This lack of information hinders the development of personalized pharmacogenomic treatment options for epilepsy in this population. The results of the current study may contribute to bridging this gap, as they shed light on the genetic associations of epilepsy in a Saudi Arabian population, which may have genetically distinct sub-populations.
Phenotype–genotype studies are essential for identifying correlations between genetic markers and epilepsy, providing a deeper understanding of its prevalence and clinical manifestations. These insights could pave the way for more targeted treatment strategies, improving both the diagnosis and management of epilepsy in the region. By incorporating genetic information into clinical practice, it may be possible to tailor treatments based on individual genetic profiles, allowing for more effective and personalized care. Furthermore, the development of pharmacogenomic drugs specifically tailored to the genetic landscape of this population could provide better outcomes than the currently available treatments, which often take a more generalized approach.
To better understand the pathogenic mechanisms underlying epilepsy in this population, experimental studies are needed to demonstrate the functional consequences of the genetic variants identified in this study. These studies could involve in vitro or in vivo models to examine how these genetic factors contribute to seizure susceptibility and the efficacy of potential treatments.

5. Conclusions

This study highlights a potential link between voltage-gated potassium channels and the risk of epilepsy, especially concerning the genetic variations in the KCNAB1 and KCNJ10 genes. Our findings suggest that variations in KCN genes may affect the clinical presentation and prognosis of epilepsy. Further genotype–phenotype studies are needed to enhance diagnostic accuracy and optimize treatment strategies. Additional research on the genetic basis of epileptic seizures will be essential for advancing pharmacogenomic approaches and expanding treatment options for patients.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/medicina61030396/s1, Table S1: Summary of the Previous Literature on Potassium Channels and Epilepsy Risk, Table S2: Description of KCN gene variants among epilepsy cases and healthy controls, Table S3: Genetic association between the KCN polymorphisms and epilepsy, Table S4: Regression analysis of KCN variants and epilepsy features, Table S5: Regression analysis of KCN variants and epilepsy features.

Author Contributions

Conceptualization, M.A.A. and L.N.A.-E.; data curation, M.A.A., L.N.A.-E., M.Y.O., D.M.R., M.K.A. and N.F.A.G.; formal analysis, M.A.A., L.N.A.-E., D.M.R. and M.K.A.; funding acquisition, M.A.A.; investigation, M.A.A., M.Y.O., A.M.A.-G., R.A.M.S. and N.F.A.G.; methodology, M.A.A., L.N.A.-E. and M.Y.O.; project administration, M.A.A.; resources, M.A.A. and L.N.A.-E.; software, D.M.R.; supervision, M.A.A. and L.N.A.-E.; validation, M.A.A., A.M.A.-G. and R.A.M.S.; visualization, L.N.A.-E., M.Y.O., D.M.R., M.K.A., A.M.A.-G., R.A.M.S. and N.F.A.G.; writing—original draft, M.A.A., L.N.A.-E., M.Y.O. and D.M.R.; writing—review and editing, M.A.A., L.N.A.-E., M.Y.O., D.M.R., M.K.A., A.M.A.-G., R.A.M.S. and N.F.A.G. All authors have read and agreed to the published version of the manuscript.

Funding

The authors thank the Deanship of Research and Graduate Studies at King Khalid University for funding this work through a Large Research Project under grant number R.G.P. 2/312/45.

Institutional Review Board Statement

This study was conducted in accordance with the ethical principles of the World Medical Association’s Declaration of Helsinki. Ethical approval was granted by the Research Ethics Committee of King Khalid University (Approval No: ECM#2019-38, Date: 26 November 2020).

Informed Consent Statement

Written informed consent was obtained from all study subjects and the legal guardians of minors before this study’s commencement after they were told about the objective and aim of this study.

Data Availability Statement

The datasets generated and/or analyzed during this study are available from the corresponding author upon reasonable request.

Acknowledgments

The authors thank the Deanship of Research and Graduate Studies at King Khalid University for its administrative and technical support, as well as for funding this work through a Large Research Project under grant number R.G.P. 2/312/45.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Beghi, E. The epidemiology of epilepsy. Neuroepidemiology 2020, 54, 185–191. [Google Scholar] [CrossRef] [PubMed]
  2. World Health Organization. Epilepsy. Available online: https://www.who.int/news-room/fact-sheets/detail/epilepsy (accessed on 7 February 2024).
  3. Neligan, A.; Hauser, W.A.; Sander, J.W. The epidemiology of the epilepsies. Handb. Clin. Neurol. 2012, 107, 113–133. [Google Scholar] [CrossRef]
  4. Al Rumayyan, A.; Alharthi, A.; Al-Rowaili, M.; Al-Mehmadi, S.; Altwaijri, W.; Alrifai, T.; Badri, M. The Prevalence of Active Epilepsy in the Kingdom of Saudi Arabia: A Cross-Sectional Study. Neuroepidemiology 2023, 57, 78–89. [Google Scholar] [CrossRef] [PubMed]
  5. AlHarbi, F.A.; Alomari, M.S.; Ghaddaf, A.A.; Abdulhamid, A.S.; Alsharef, J.F.; Makkawi, S. Public awareness and attitudes toward epilepsy in Saudi Arabia: A systematic review and meta-analysis. Epilepsy Behav. 2021, 124, 108314. [Google Scholar] [CrossRef]
  6. Muthaffar, O.Y.; Jan, M.M. Public awareness and attitudes toward epilepsy in Saudi Arabia is improving. Neurosci. J. 2014, 19, 124–126. [Google Scholar] [PubMed]
  7. Shorvon, S.D. The etiologic classification of epilepsy. Epilepsia 2011, 52, 1052–1057. [Google Scholar] [CrossRef] [PubMed]
  8. Giourou, E.; Stavropoulou-Deli, A.; Giannakopoulou, A.; Kostopoulos, G.K.; Koutroumanidis, M. Introduction to epilepsy and related brain disorders. In Cyberphysical Systems for Epilepsy and Related Brain Disorders: Multi-Parametric Monitoring and Analysis for Diagnosis and Optimal Disease Management; Springer: Cham, Switzerland, 2015; pp. 11–38. [Google Scholar] [CrossRef]
  9. Sirven, J.I. Epilepsy: A spectrum disorder. Cold Spring Harb. Perspect. Med. 2015, 5, a022848. [Google Scholar] [CrossRef] [PubMed]
  10. Steinlein, O.K. Genetics and epilepsy. Dialogues Clin. Neurosci. 2008, 10, 29–38. [Google Scholar] [CrossRef] [PubMed]
  11. Greenberg, D.A.; Pal, D.K. The state of the art in the genetic analysis of the epilepsies. Curr. Neurol. Neurosci. Rep. 2007, 7, 320–328. [Google Scholar] [CrossRef]
  12. Chen, T.; Giri, M.; Xia, Z.; Subedi, Y.N.; Li, Y. Genetic and epigenetic mechanisms of epilepsy: A review. Neuropsychiatr. Dis. Treat. 2017, 13, 1841–1859. [Google Scholar] [CrossRef] [PubMed]
  13. Köhling, R.; Wolfart, J. Potassium channels in epilepsy. Cold Spring Harb. Perspect. Med. 2016, 6, a022871. [Google Scholar] [CrossRef] [PubMed]
  14. Noebels, J.L.; Avoli, M.; Rogawski, M.A.; Olsen, R.W.; Delgado-Escueta, A.V. Jasper’s Basic Mechanisms of the Epilepsies, 4th ed.; National Center for Biotechnology Information: Bethesda, MD, USA, 2012. [PubMed]
  15. Villa, C.; Combi, R. Potassium Channels and Human Epileptic Phenotypes: An Updated Overview. Front. Cell Neurosci. 2016, 10, 81. [Google Scholar] [CrossRef] [PubMed]
  16. Shah, N.H.; Aizenman, E. Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration. Transl. Stroke Res. 2014, 5, 38–58. [Google Scholar] [CrossRef] [PubMed]
  17. Paulhus, K.; Ammerman, L.; Glasscock, E. Clinical Spectrum of KCNA1 Mutations: New Insights into Episodic Ataxia and Epilepsy Comorbidity. Int. J. Mol. Sci. 2020, 21, 2802. [Google Scholar] [CrossRef] [PubMed]
  18. Eunson, L.H.; Rea, R.; Zuberi, S.M.; Youroukos, S.; Panayiotopoulos, C.P.; Liguori, R.; Avoni, P.; McWilliam, R.C.; Stephenson, J.B.P.; Hanna, M.G.; et al. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann. Neurol. 2000, 48, 647–656. [Google Scholar] [CrossRef] [PubMed]
  19. Browne, D.L.; Gancher, S.T.; Nutt, J.G.; Brunt, E.R.P.; Smith, E.A.; Kramer, P.; Litt, M. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat. Genet. 1994, 8, 136–140. [Google Scholar] [CrossRef] [PubMed]
  20. Imbrici, P.; D’Adamo, M.C.; Kullmann, D.M.; Pessia, M. Episodic ataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human potassium channels Kv1.4-1.1/Kvβ1.1 and Kv1.4-1.1/Kvβ1.2. Eur. J. Neurosci. 2006, 24, 3073–3083. [Google Scholar] [CrossRef] [PubMed]
  21. Verdura, E.; Fons, C.; Schlüter, A.; Ruiz, M.; Fourcade, S.; Casasnovas, C.; Castellano, A.; Pujol, A. Complete loss of KCNA1 activity causes neonatal epileptic encephalopathy and dyskinesia. J. Med. Genet. 2020, 57, 132–137. [Google Scholar] [CrossRef]
  22. Gong, P.; Xue, J.; Jiao, X.R.; Zhang, Y.H.; Yang, Z.X. Genotype and phenotype of children with KCNA2 gene related developmental and epileptic encephalopathy. Zhonghua Er Ke Za Zhi = Chin. J. Pediatr. 2020, 58, 35–40. [Google Scholar] [CrossRef] [PubMed]
  23. Pena, S.D.; Coimbra, R.L. Ataxia and myoclonic epilepsy due to a heterozygous new mutation in KCNA2: Proposal for a new channelopathy. Clin. Genet. 2015, 87, e1–e3. [Google Scholar] [CrossRef] [PubMed]
  24. Jorge, B.S.; Campbell, C.M.; Miller, A.R.; Rutter, E.D.; Gurnett, C.A.; Vanoye, C.G.; George, A.L.; Kearney, J.A. Voltage-gated potassium channel KCNV2 (Kv8.2) contributes to epilepsy susceptibility. Proc. Natl. Acad. Sci. USA 2011, 108, 5443–5448. [Google Scholar] [CrossRef] [PubMed]
  25. Syrbe, S.; Hedrich, U.B.; Riesch, E.; Djémié, T.; Müller, S.; Møller, R.S.; Maher, B.; Hernandez-Hernandez, L.; Synofzik, M.; Caglayan, H.S.; et al. De novo loss- or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nat. Genet. 2015, 47, 393–399. [Google Scholar] [CrossRef] [PubMed]
  26. Czirják, G.; Tóth, Z.E.; Enyedi, P. Characterization of the heteromeric potassium channel formed by kv2.1 and the retinal subunit kv8.2 in Xenopus oocytes. J. Neurophysiol. 2007, 98, 1213–1222. [Google Scholar] [CrossRef] [PubMed]
  27. Heilstedt, H.A.; Burgess, D.L.; Anderson, A.E.; Chedrawi, A.; Tharp, B.; Lee, O.; Kashork, C.D.; Starkey, D.E.; Noebels, J.L.; Shaffer, L.G.; et al. Loss of the potassium channel beta-subunit gene, KCNAB2, is associated with epilepsy in patients with 1p36 deletion syndrome. Epilepsia 2001, 42, 1103–1111. [Google Scholar] [CrossRef] [PubMed]
  28. Shang, L.; Lucchese, C.J.; Haider, S.; Tucker, S.J. Functional characterization of missense variations in the Kir4.1 potassium channel (KCNJ10) associated with seizure susceptibility. Brain Res. Mol. Brain Res. 2005, 139, 178–183. [Google Scholar] [CrossRef] [PubMed]
  29. Bockenhauer, D.; Feather, S.; Stanescu, H.C.; Bandulik, S.; Zdebik, A.A.; Reichold, M.; Tobin, J.; Lieberer, E.; Sterner, C.; Landoure, G.; et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N. Engl. J. Med. 2009, 360, 1960–1970. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  30. Scholl, U.I.; Choi, M.; Liu, T.; Ramaekers, V.T.; Häusler, M.G.; Grimmer, J.; Tobe, S.W.; Farhi, A.; Nelson-Williams, C.; Lifton, R.P. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc. Natl. Acad. Sci. USA 2009, 106, 5842–5847. [Google Scholar] [CrossRef] [PubMed]
  31. Zheng, Y.; Chen, J. Voltage-gated potassium channels and genetic epilepsy. Front. Neurol. 2024, 15, 1466075. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  32. Alghamdi, M.A.; Al-Eitan, L.N.; Asiri, A.; Rababa’h, D.M.; Alqahtani, S.A.; Aldarami, M.S.; Alsaeedi, M.A.; Almuidh, R.S.; Alzahrani, A.A.; Sakah, A.H.; et al. Association of sodium voltage-gated channel genes polymorphisms with epilepsy risk and prognosis in the Saudi population. Ann. Med. 2022, 54, 1938–1951. [Google Scholar] [CrossRef] [PubMed]
  33. Al-Eitan, L.N.; Al-Dalalah, I.M.; Mustafa, M.M.; Alghamdi, M.A.; Elshammari, A.K.; Khreisat, W.H.; Al-Quasmi, M.N.; Aljamal, H.A. Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: A pharmacogenetic and case-control study. Pharmacogenomics Pers. Med. 2019, 12, 225–233. [Google Scholar] [CrossRef] [PubMed]
  34. Al-Eitan, L.N.; Al-Dalalah, I.M.; Mustafa, M.M.; A Alghamdi, M.; Elshammari, A.K.; Khreisat, W.H.; A Aljamal, H. Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients. Pharmacogenomics Pers. Med. 2019, 12, 87–95. [Google Scholar] [CrossRef] [PubMed]
  35. Al-Eitan, L.N.; Al-Dalalah, I.M.; Aljamal, H.A. Effects of GRM4, SCN2A and SCN3B polymorphisms on antiepileptic drugs responsiveness and epilepsy susceptibility. Saudi Pharm. J. 2019, 27, 731–737. [Google Scholar] [CrossRef] [PubMed]
  36. Kockum, I.; Huang, J.; Stridh, P. Overview of genotyping technologies and methods. Curr. Protoc. 2023, 3, e727. [Google Scholar] [CrossRef]
  37. Kearney, J.A.; Rakhade, S.N. Sample Size Determination in Epilepsy Trials. Epilepsia 2019, 60, 634–641. [Google Scholar]
  38. Guerreiro, C.A. Epilepsy: Is there hope? Indian J. Med. Res. 2016, 144, 657–660. [Google Scholar] [CrossRef] [PubMed]
  39. Thijs, R.D.; Surges, R.; O’Brien, T.J.; Sander, J.W. Epilepsy in adults. Lancet 2019, 393, 689–701. [Google Scholar] [CrossRef] [PubMed]
  40. Rogawski, M.A.; Löscher, W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 2004, 5, 553–564. [Google Scholar] [CrossRef] [PubMed]
  41. Niday, Z.; Tzingounis, A.V. Potassium Channel Gain of Function in Epilepsy: An Unresolved Paradox. Neuroscientist 2018, 24, 368–380. [Google Scholar] [CrossRef] [PubMed]
  42. Busolin, G.; Malacrida, S.; Bisulli, F.; Striano, P.; Di Bonaventura, C.; Egeo, G.; Pasini, E.; Cianci, V.; Ferlazzo, E.; Bianchi, A.; et al. Association of intronic variants of the KCNAB1 gene with lateral temporal epilepsy. Epilepsy Res. 2011, 94, 110–116. [Google Scholar] [CrossRef] [PubMed]
  43. Zhu, H.; Zhang, M.; Fu, Y.; Long, H.; Xiao, W.; Feng, L.; Xiao, B.; Zhou, L. Effects of AQP4 and KCNJ10 Gene Polymorphisms on Drug Resistance and Seizure Susceptibility in Chinese Han Patients with Focal Epilepsy. Neuropsychiatr. Dis. Treat. 2020, 16, 119–129. [Google Scholar] [CrossRef] [PubMed]
  44. Al-Eitan, L.N.; Al-Dalalah, I.M.; Elshammari, A.K.; Khreisat, W.H.; Almasri, A.Y. The Impact of Potassium Channel Gene Polymorphisms on Antiepileptic Drug Responsiveness in Arab Patients with Epilepsy. J. Pers. Med. 2018, 8, 37. [Google Scholar] [CrossRef] [PubMed]
  45. Pendo, K.; DeGiorgio, C.M. Vitamin D3 for the Treatment of Epilepsy: Basic Mechanisms, Animal Models, and Clinical Trials. Front. Neurol. 2016, 7, 218. [Google Scholar] [CrossRef] [PubMed]
  46. Teagarden, D.L.; Meador, K.J.; Loring, D.W. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 2014, 108, 1352–1356. [Google Scholar] [CrossRef] [PubMed]
  47. Banerjee, P.N.; Filippi, D.; Allen Hauser, W. The descriptive epidemiology of epilepsy—A review. Epilepsy Res. 2009, 85, 31–45. [Google Scholar] [CrossRef] [PubMed]
  48. Abdel Ghaffar, N.F.; Asiri, R.N.; Al-Eitan, L.N.; Alamri, R.S.; Alshyarba, R.M.; Alrefeidi, F.A.; Asiri, A.; Alghamdi, M.A. Improving public stigma, sociocultural beliefs, and social identity for people with epilepsy in the Aseer region of Saudi Arabia. Epilepsy Behav. Rep. 2021, 16, 100442. [Google Scholar] [CrossRef] [PubMed]
  49. Al-Eitan, L.N.; Al-Dalala, I.M.; Elshammari, A.K.; Khreisat, W.H.; Nimiri, A.F.; Alnaamneh, A.H.; A Aljamal, H.; A Alghamdi, M. Genetic Association of Epilepsy and Anti-Epileptic Drugs Treatment in Jordanian Patients. Pharmacogenomics Pers. Med. 2020, 13, 503–510. [Google Scholar] [CrossRef] [PubMed]
Table 1. General and clinical characteristics of the epilepsy patients.
Table 1. General and clinical characteristics of the epilepsy patients.
General/Clinical CharacteristicsMean/Frequency
Age at diagnosis9.7 ± 7.986
BMI23.2 ± 7.789
Duration of first seizure (sec)8.703 ± 14.032
GenderMale51%
Female49%
Time to remissionNo28.5%
Yes (seizure-free immediately)52.3%
Yes (seizure-free within 6 months)18.7%
Epilepsy classificationFocal (partial) onset16%
Generalized onset76%
Combined generalized and focal onset8%
Seizure classificationMotor94.6%
Non-motor5.4%
History of febrile seizureYes11.9%
No88.1%
Family history of epilepsyYes33.9%
No66.1%
AED drugYes6%
No94%
First drug responsivenessYes64%
No36%
RelapseYes45%
No55%
Periodic epilepsyYes21%
No79%
Table 2. Description of KCN gene variants among epilepsy cases and healthy controls.
Table 2. Description of KCN gene variants among epilepsy cases and healthy controls.
GeneSNP IDSNP Position aCases (n = 296)Controls (n =293)
MA bMAF cHWE d p-ValueMAF cHWE d p-Value
KCNV2rs70290129:2717698C0.360.0330.400.18
KCNAB1rs42951333:156516479A0.470.480.490.003
rs27202813:156512429G0.470.100.440.012
rs173524083:156484880G0.280.190.290.032
rs15467503:156468103C0.480.0620.476 × 10−4
rs22805613:156460417G0.441.000.471 × 10−3
rs168261993:156452654G0.080.0440.050.57
KCNJ10rs124029691:160050447C0.011.000.010.017
rs11866751:160069294A0.020.110.030.019
a Chromosome positions are based on NCBI Human Genome Assembly Build. b MA: minor allele. c MAF: minor allele frequency. d HWE: Hardy—Weinberg equilibrium.
Table 3. Genetic association between KCN polymorphisms and epilepsy.
Table 3. Genetic association between KCN polymorphisms and epilepsy.
GeneSNP IDAllelic and Genotypic Frequencies in Cases and Controls
Allele/GenotypeCases (n = 495)Controls (n = 497)p-Value *
KCNAB1rs3755631C539 (91%)550 (94%0.04
G53 (0.09%)34 (0.06%)
rs4679773C300 (51%)330 (57%)0.04
G288 (49%)250 (43%)
KCNJ10rs2820585G/G204 (68.9%)225 (77.3%)0.034
A/G86 (29.1%)58 (19.9%)
A/A6 (2%)8 (2.8%)
rs946420C/C204 (69.2%)223 (77.2%)0.045
C/A85 (28.8%)58 (20.1%)
A/A6 (2%)8 (2.8%)
rs1186679C/C203 (68.8%)226 (77.4%)0.021
C/T87 (29.5%)58 (19.9%)
T/T5 (1.7%)8 (2.7%)
rs61822012A/A203 (69.3%)226 (77.7%)0.048
A/G84 (28.7%)58 (19.9%)
G/G6 (2%)7 (2.4%)
rs1186685A495 (84%)513 (88%)0.04
G97 (17%)71 (13%)
rs12122979A/A205 (69.3%)229 (78.4%)0.018
G/A85 (28.7%)55 (18.8%)
G/G6 (2%)8 (2.7%)
* p < 0.05 is considered significant.
Table 4. Regression analysis of KCN variants in relation to epilepsy traits.
Table 4. Regression analysis of KCN variants in relation to epilepsy traits.
GeneSNP IDAge at DiagnosisDuration of First Seizure BMIVIT.DVIT B12
KCNA2rs38878200.8320.2650.1330.0220.856
KCNV2rs109677050.5100.0050.7840.7940.742
rs15467500.0450.7760.2490.9040.320
rs7283820.8660.0690.2440.3260.031
rs9464200.010.1890.1460.0930.469
rs112653130.3200.0020.5730.1720.778
rs618220120.010.3300.1180.0930.469
rs11866850.010.1890.1460.1460.469
Linear regression using ANOVA test. p-value <0.05 is significant.
Table 5. Regression analysis exploring the association between KCN variants and epilepsy features.
Table 5. Regression analysis exploring the association between KCN variants and epilepsy features.
GeneSNP IDGenderRelapseHistory of Febrile SeizurePeriodic SeizureTime to RemissionDrug Responsiveness Drug LevelFamily History of EpilepsyEpilepsy ClassificationSeizure Classification
KCNA1rs22279100.1150.3160.4400.5310.8030.7680.1420.0390.8250.882
rs79744590.3720.5720.0270.1910.1760.5250.8150.5440.3310.954
KCNV2rs109677280.7110.2090.3270.3650.7350.5440.4620.5560.0330.281
KCNA-B1rs9923530.7870.0080.9340.5080.3550.7240.4660.3760.1310.730
rs46797730.1670.7320.3240.0290.3920.3700.2910.0110.3310.500
rs15510660.6650.7500.5990.1750.5130.2070.6780.0930.0200.997
rs22800310.7230.7150.6830.7820.2540.0420.5220.8510.9540.456
KCNJ10rs10530740.0040.4860.4090.0860.1340.7910.1280.5450.6470.606
rs28205850.2030.7870.3210.0390.6430.0080.2790.4480.6520.381
rs9464200.1760.7410.2050.1530.7810.0060.2090.4030.8960.297
rs11866790.1880.7520.3290.0380.6120.0080.2840.4820.6480.387
rs46568730.4400.7980.3130.0100.0490.8790.0820.9470.4820.786
rs173757480.2700.3990.1930.5420.0010.6590.7290.1400.6160.208
rs618220120.2170.6510.1970.1610.6690.0040.2030.4250.888 0.290
rs18905320.6650.6930.3980.0150.0700.8930.1370.5400.5850.890
rs11866890.3240.9840.0200.5360.4170.0840.0721.0000.7120.436
rs11866850.1760.7410.2050.1530.7810.0060.2090.4030.8960.297
rs121229790.2510.2250.4370.5120.5910.0560.3720.0470.9020.629
KCNJ9rs27532680.5090.2380.2130.3680.2310.4290.4370.1340.0240.172
Linear regression using Pearson’s r test. p-value < 0.05 is significant.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Alghamdi, M.A.; AL-Eitan, L.N.; Otaif, M.Y.; Rababa’h, D.M.; Alasmar, M.K.; Al-Garni, A.M.; Saleh, R.A.M.; Abdel Ghaffar, N.F. Association of Voltage-Gated Potassium Channel Polymorphisms with the Risk and Prognosis of Epilepsy in the Saudi Population: A Case–Control Study. Medicina 2025, 61, 396. https://doi.org/10.3390/medicina61030396

AMA Style

Alghamdi MA, AL-Eitan LN, Otaif MY, Rababa’h DM, Alasmar MK, Al-Garni AM, Saleh RAM, Abdel Ghaffar NF. Association of Voltage-Gated Potassium Channel Polymorphisms with the Risk and Prognosis of Epilepsy in the Saudi Population: A Case–Control Study. Medicina. 2025; 61(3):396. https://doi.org/10.3390/medicina61030396

Chicago/Turabian Style

Alghamdi, Mansour A., Laith N. AL-Eitan, Mansour Y. Otaif, Doaa M. Rababa’h, Maryam K. Alasmar, Abdulaziz M. Al-Garni, Rayyh A. M. Saleh, and Nawal F. Abdel Ghaffar. 2025. "Association of Voltage-Gated Potassium Channel Polymorphisms with the Risk and Prognosis of Epilepsy in the Saudi Population: A Case–Control Study" Medicina 61, no. 3: 396. https://doi.org/10.3390/medicina61030396

APA Style

Alghamdi, M. A., AL-Eitan, L. N., Otaif, M. Y., Rababa’h, D. M., Alasmar, M. K., Al-Garni, A. M., Saleh, R. A. M., & Abdel Ghaffar, N. F. (2025). Association of Voltage-Gated Potassium Channel Polymorphisms with the Risk and Prognosis of Epilepsy in the Saudi Population: A Case–Control Study. Medicina, 61(3), 396. https://doi.org/10.3390/medicina61030396

Article Metrics

Back to TopTop